Abstract: The present invention relates to methods for the diagnosis of NAFLD in a subject, and for the differential diagnosis of NASH or steatosis in a subject suffering from NAFLD, based on the determination in a sample of metabolic markers, particularly lipid metabolic markers.

Abstract: The present invention relates to methods for the diagnosis of NAFLD in a subject, and for the differential diagnosis of NASH or steatosis in a subject suffering from NAFLD, based on the determination in a sample of metabolic markers, particularly lipid metabolic markers.

Abstract: The present invention is directed to a diagnostic method for non-alcoholic fatty liver disease (NAFLD) and to a method for monitoring the progression of the disease based on the determination of the levels of different metabolites. The invention also provides a method for determining the efficacy of an NAFLD therapy and a method for identification of compounds suitable for the treatment of NAFLD.

Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).

Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).

Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).

Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).

Abstract: Phosphorylated Sp1 can be used as a marker for in vitro diagnosis of non-alcoholic steatohepatitis (NASH) as well as a therapeutical target of said condition.

Abstract: The invention relates to a method of diagnosing non-alcoholic steatohepatitis (NASH) using molecular markers. The inventive method consists in detecting and quantifying, in vitro in a hepatic tissue sample, the levels of a protein which can be used as a NASH molecular marker and which is selected from apolipoprotein A1, sub-unit ? of the mitochondrial ATPase, leukotriene A4 hydrolase, keratin 18, guanidine acetate N-methyltransferase, superoxide dismutase, albumin, antioxidant protein 2 (isoform 1), prohibitin 1, methionine adenosyl transferase, long-chain acyl CoA dehydrogenase, selenium binding protein, antioxidant protein 2 (isoform 2), and combinations of same. The invention further consists in comparing the results obtained with the normal values of said proteins in healthy hepatic tissue. Said method can be used to diagnose NASH and/or to assess a patient's potential risk of developing NASH.